May 29
BSE+NSE Vol: 3.16 lacs
News and Views
A sharp decline in Glaxosmithkline Pharmaceuticals Ltd has pushed the stock to a fresh 52-week low of Rs 2215 on 29 May 2026, marking a 31.11% drop over the past year, significantly underperforming the Sensex's 7.60% decline in the same period.
Read full news article
Glaxosmithkline Pharmaceuticals Ltd (NSE: 793005) has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish indicators. Despite a modest day gain of 0.78%, the stock’s broader technical parameters reveal a transition from bearish to mildly bearish trends, underscoring the need for cautious investor appraisal amid mixed signals from key momentum indicators such as MACD, RSI, and moving averages.
Read full news article
Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. The company’s recent downgrade from a Hold to a Sell rating by MarketsMOJO, accompanied by a Mojo Score of 37.0, reflects growing concerns over its near-term price performance amid weakening technical signals and a subdued market environment.
Read full news article
Glaxosmithkline Pharmaceuticals Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a modest day decline of 0.42%, the stock’s technical indicators reveal a nuanced picture that investors must carefully analyse amid broader market trends.
Read full news article
Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s recent downgrade from a Hold to a Sell rating reflects deteriorating price action and weakening momentum across multiple timeframes, raising concerns for investors amid a challenging market backdrop.
Read full news article
Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 May 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
May 11: Stock opens at Rs.2,435.95 amid broad market decline
May 13: Q4 FY26 results reveal margin compression despite strong ROE
May 14: Flat quarterly performance reported amid shifting financial trends
May 15: Week closes at Rs.2,439.75, down 1.81% for the week
Glaxosmithkline Pharmaceuticals Ltd has declared a dividend. Dividend Details: - Percentage announced: 570% - Amount per share: 12 per share - Ex-date: Nov-07-2024 Dividend Yield: 0% Total Returns by Period: In the 3 Months period, the price return was -5.94%, the dividend return was 2.20%, resulting in a total return of -3.74%. In the 6 Months period, the price return was -1.54%, the dividend return was 2.30%, leading to a total return of 0.76%. Over the 1 Year period, the price return was -15.05%, the dividend return was 2.05%, culminating in a total return of -13.0%. In the 2 Years period, the price return was 22.8%, the dividend return was 4.28%, resulting in a total return of 27.08%. For the 3 Years period, the price return was 90.57%, the dividend return was 10.19%, leading to a total return of 100.76%. In the 4 Years period, the price return was 63.56%, the dividend return was 12.80%, culmina...
Read full news articleGlaxoSmithKline Pharmaceuticals Ltd's latest financial results for the quarter ended March 2026 present a mixed operational picture. The company reported net sales of ₹995.30 crores, reflecting a sequential decline of 4.41% compared to the previous quarter, marking the second consecutive quarter of revenue contraction. Year-on-year, however, net sales showed a modest growth of 2.15%. In terms of profitability, the net profit for the same quarter was ₹277.86 crores, which also represented a sequential decline of 6.01% from the prior quarter. On a year-on-year basis, net profit exhibited a growth of 5.70%. The operating margin stood at 35.26%, slightly down from 35.66% in the previous quarter, indicating some pressure on profitability metrics despite maintaining a strong position relative to industry averages. The company has demonstrated exceptional return on equity at 55.83%, highlighting its efficiency i...
Read full news articleAnnouncementAnnual Compliance Secretarial Report for year ended March 2026
As per attachment
As per attachment
Corporate Actions
No Upcoming Board Meetings
Glaxosmithkline Pharmaceuticals Ltd has declared 570% dividend, ex-date: 29 May 26
No Splits history available
Glaxosmithkline Pharmaceuticals Ltd has announced 1:1 bonus issue, ex-date: 11 Sep 18
No Rights history available
